San Diego-based Companion Medical has raised $3 million in an ongoing Series B round led by an investment from Eli Lilly, Xconomy is reporting. Founded some 16 months ago, the startup has developed a smart insulin injector pen that connects to a smartphone via Bluetooth. It plans to use the fresh capital to attempt to complete testing and seek a 510(k) FDA clearance, marking the first time such Bluetooth pen has been cleared by the agency.

“The FDA has not yet cleared a Bluetooth pen (to our knowledge); we hope to be the first,” Companion Medical CEO Sean Saint said.

The company’s device works with a companion app to track the amount of insulin injected and time of use; the application also features a dose calculator and missed dose alarms.

In April of last year, Companion Medical received an undisclosed investment from the Swedish medical research company Diamyd Medical.